IBDEI0A2 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4468,1,4,0)
 ;;=4^H61.002
 ;;^UTILITY(U,$J,358.3,4468,2)
 ;;=^5006500
 ;;^UTILITY(U,$J,358.3,4469,0)
 ;;=L81.0^^21^279^21
 ;;^UTILITY(U,$J,358.3,4469,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4469,1,3,0)
 ;;=3^Postinflammatory Hyperpigmentation
 ;;^UTILITY(U,$J,358.3,4469,1,4,0)
 ;;=4^L81.0
 ;;^UTILITY(U,$J,358.3,4469,2)
 ;;=^5009310
 ;;^UTILITY(U,$J,358.3,4470,0)
 ;;=L81.7^^21^279^15
 ;;^UTILITY(U,$J,358.3,4470,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4470,1,3,0)
 ;;=3^Pigmented Purpuric Dermatosis
 ;;^UTILITY(U,$J,358.3,4470,1,4,0)
 ;;=4^L81.7
 ;;^UTILITY(U,$J,358.3,4470,2)
 ;;=^5009317
 ;;^UTILITY(U,$J,358.3,4471,0)
 ;;=L29.8^^21^279^32
 ;;^UTILITY(U,$J,358.3,4471,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4471,1,3,0)
 ;;=3^Pruritus NEC
 ;;^UTILITY(U,$J,358.3,4471,1,4,0)
 ;;=4^L29.8
 ;;^UTILITY(U,$J,358.3,4471,2)
 ;;=^5009152
 ;;^UTILITY(U,$J,358.3,4472,0)
 ;;=Z85.828^^21^279^10
 ;;^UTILITY(U,$J,358.3,4472,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4472,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,4472,1,4,0)
 ;;=4^Z85.828
 ;;^UTILITY(U,$J,358.3,4472,2)
 ;;=^5063443
 ;;^UTILITY(U,$J,358.3,4473,0)
 ;;=B36.0^^21^279^18
 ;;^UTILITY(U,$J,358.3,4473,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4473,1,3,0)
 ;;=3^Pityriasis Versicolor
 ;;^UTILITY(U,$J,358.3,4473,1,4,0)
 ;;=4^B36.0
 ;;^UTILITY(U,$J,358.3,4473,2)
 ;;=^5000608
 ;;^UTILITY(U,$J,358.3,4474,0)
 ;;=Z92.3^^21^279^8
 ;;^UTILITY(U,$J,358.3,4474,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4474,1,3,0)
 ;;=3^Personal Hx of Irradiation (Therapeutic)
 ;;^UTILITY(U,$J,358.3,4474,1,4,0)
 ;;=4^Z92.3
 ;;^UTILITY(U,$J,358.3,4474,2)
 ;;=^5063637
 ;;^UTILITY(U,$J,358.3,4475,0)
 ;;=Z91.82^^21^279^11
 ;;^UTILITY(U,$J,358.3,4475,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4475,1,3,0)
 ;;=3^Personal Hx of Military Deployment
 ;;^UTILITY(U,$J,358.3,4475,1,4,0)
 ;;=4^Z91.82
 ;;^UTILITY(U,$J,358.3,4475,2)
 ;;=^5063626
 ;;^UTILITY(U,$J,358.3,4476,0)
 ;;=L66.0^^21^279^38
 ;;^UTILITY(U,$J,358.3,4476,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4476,1,3,0)
 ;;=3^Pseudopelade
 ;;^UTILITY(U,$J,358.3,4476,1,4,0)
 ;;=4^L66.0
 ;;^UTILITY(U,$J,358.3,4476,2)
 ;;=^191705
 ;;^UTILITY(U,$J,358.3,4477,0)
 ;;=Z85.820^^21^279^9
 ;;^UTILITY(U,$J,358.3,4477,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4477,1,3,0)
 ;;=3^Personal Hx of Malig Melanoma of Skin
 ;;^UTILITY(U,$J,358.3,4477,1,4,0)
 ;;=4^Z85.820
 ;;^UTILITY(U,$J,358.3,4477,2)
 ;;=^5063441
 ;;^UTILITY(U,$J,358.3,4478,0)
 ;;=Z87.2^^21^279^12
 ;;^UTILITY(U,$J,358.3,4478,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4478,1,3,0)
 ;;=3^Personal Hx of Skin Diseases
 ;;^UTILITY(U,$J,358.3,4478,1,4,0)
 ;;=4^Z87.2
 ;;^UTILITY(U,$J,358.3,4478,2)
 ;;=^5063484
 ;;^UTILITY(U,$J,358.3,4479,0)
 ;;=L08.0^^21^279^43
 ;;^UTILITY(U,$J,358.3,4479,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4479,1,3,0)
 ;;=3^Pyoderma
 ;;^UTILITY(U,$J,358.3,4479,1,4,0)
 ;;=4^L08.0
 ;;^UTILITY(U,$J,358.3,4479,2)
 ;;=^5009078
 ;;^UTILITY(U,$J,358.3,4480,0)
 ;;=L73.1^^21^279^37
 ;;^UTILITY(U,$J,358.3,4480,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4480,1,3,0)
 ;;=3^Pseudofolliculitis Barbae
 ;;^UTILITY(U,$J,358.3,4480,1,4,0)
 ;;=4^L73.1
 ;;^UTILITY(U,$J,358.3,4480,2)
 ;;=^5009284
 ;;^UTILITY(U,$J,358.3,4481,0)
 ;;=L42.^^21^279^16
 ;;^UTILITY(U,$J,358.3,4481,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4481,1,3,0)
 ;;=3^Pityriasis Rosea
 ;;^UTILITY(U,$J,358.3,4481,1,4,0)
 ;;=4^L42.
 ;;^UTILITY(U,$J,358.3,4481,2)
 ;;=^94726
 ;;^UTILITY(U,$J,358.3,4482,0)
 ;;=L44.0^^21^279^17
 ;;^UTILITY(U,$J,358.3,4482,1,0)
 ;;=^358.31IA^4^2
